As a TKI-relevant example, analysis of the degree of tumor shrinkage in response to ALK inhibitors in patients with EML4-ALK positive lung cancer revealed a highly significant positive correlation with overall and progression-free survival [26]. The gene discussed is EML4; the disease is lung carcinoma.